Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh (VRTX34) Price & Analysis

Q: Is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh overvalued?

According to Wall Street analysts Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh?

Currently, no hedge funds are holding shares in BR:VRTX34

― Followers

VRTX34 Stock Chart & Stats

R$87.74

-R$1.18(-1.33%)

Sep 04, 2026

―

Day’s Range― - ―

52-Week RangeR$60.00 - R$89.01

Previous CloseN/A

VolumeN/A

Average Volume (3M)6.26K

Market Cap

R$709.64B

Enterprise ValueR$49.22K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)11536.8

Beta-0.20

Next Earnings

Nov 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding8,110,749,500

10 Day Avg. Volume1,068

30 Day Avg. Volume6,257

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh News

Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital

Roth Capital raised the firm’s price target on Arcturus Therapeutic (ARCT) s to $41 from $20 and keeps...

5d ago

ARCT

VRTX

Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley

Morgan Stanley analyst Terence Flynn resumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $665 price...

6d ago

VRTX

Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals

Vertex Pharmaceuticals (VRTX) announced the successful completion of the acquisition of Crinetics Pharmaceuticals (CRNX). Vertex also announced the...

6d ago

CRNX

VRTX

Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs

Goldman Sachs analysts added Vertex Pharmaceuticals (VRTX) to the firm’s US Conviction List as part of its monthly...

7d ago

VRTX

Argenx price target raised to $1,250 from $1,230 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,250 from $1,230 and keeps an Overweight...

7d ago

ARGX

VRTX

Private Markets: $1B for Base Power, $545M for Whatnot

Two fast growing private companies are drawing attention next week as Base Power rolls out its new grid...

18d ago

Private Markets: Databricks secures $5B as Kalshi targets $40B valuation

Databricks’ $5B strategic raise at a $190B valuation underscores the momentum in AI infrastructure, as Kalshi reportedly seeks...

22d ago

IBM

Vertex Pharmaceuticals added to ‘US 1 List’ at BofA

BofA analysts added Vertex Pharmaceuticals (VRTX) to the firm’s “US 1 List.” The list represents BofA’s best investment...

28d ago

VRTX

Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss

As previously reported, Guggenheim downgraded Sionna Therapeutics (SION) to Neutral from Buy and removed the firm’s prior price...

28d ago

SION

VRTX

Vertex Pharmaceuticals price target raised to $672 from $605 at BofA

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy...

28d ago

SION

VRTX

Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating

BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target...

27d ago

VRTX

Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF

Wolfe Research analyst Andy Chen has maintained their bullish stance on VRTX stock, giving a Buy rating today....

1M ago

VRTX

Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside

Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Yee from...

1M ago

VRTX

Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained

Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals, boosting the price target to...

1M ago

VRTX

VRTX34 FAQ

What was Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price range in the past 12 months?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh lowest stock price was R$60.00 and its highest was R$89.01 in the past 12 months.

What is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s market cap?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s market cap is R$709.64B.

When is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s upcoming earnings report date?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s upcoming earnings report date is Nov 09, 2026 which is in 63 days.

How were Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s earnings last quarter?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh released its earnings results on Aug 03, 2026. The company reported R$0.005 earnings per share for the quarter.

Is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh overvalued?

According to Wall Street analysts Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh pay dividends?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh does not currently pay dividends.

What is Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s EPS estimate?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh have?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh has 8,110,749,500 shares outstanding.

What happened to Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh’s price movement after its last earnings report?

Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh reported an EPS of R$0.005 in its last earnings report. Following the earnings report the stock price went up 2.225%.

Which hedge fund is a major shareholder of Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh?

Currently, no hedge funds are holding shares in BR:VRTX34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology